Last reviewed · How we verify

Sequential therapy 10 days — Competitive Intelligence Brief

Sequential therapy 10 days (Sequential therapy 10 days) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic. Area: Infectious Diseases.

marketed Antibiotic Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Sequential therapy 10 days (Sequential therapy 10 days) — Incheon St.Mary's Hospital. Sequential therapy is a treatment approach that involves a combination of antibiotics to treat bacterial infections.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sequential therapy 10 days TARGET Sequential therapy 10 days Incheon St.Mary's Hospital marketed Antibiotic
Avelox moxifloxacin Bayer AG marketed Fluoroquinolone antibiotic (fourth-generation) DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A 1999-12-10
Zithromax azithromycin Pfizer Inc. marketed Macrolide antibiotic (azalide) Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor 1991-11-01
Cipro ciprofloxacin Bayer AG marketed Fluoroquinolone antibiotic DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A 1987-10-22
Rocephin ceftriaxone Generic (originally Roche) marketed Cephalosporin antibiotic (third-generation) Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A 1984-12-21
Amoxil amoxicillin Generic (originally Beecham/GSK) marketed Aminopenicillin (Beta-lactam antibiotic) 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C 1972-01-01
Cleocin clindamycin Generic (originally Upjohn/Pfizer) marketed Lincosamide antibiotic 50S ribosomal protein L10 1970-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Antibiotic class)

  1. Bausch Health Americas, Inc. · 2 drugs in this class
  2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  3. BioVersys AG · 1 drug in this class
  4. Bosnalijek D.D · 1 drug in this class
  5. Capital Medical University · 1 drug in this class
  6. Dr. Reddy's Laboratories Limited · 1 drug in this class
  7. Incheon St.Mary's Hospital · 1 drug in this class
  8. Jomaa Pharma GmbH · 1 drug in this class
  9. King Abdulaziz University · 1 drug in this class
  10. Menzies School of Health Research · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sequential therapy 10 days — Competitive Intelligence Brief. https://druglandscape.com/ci/sequential-therapy-10-days. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: